Oxford Nanopore Technologies is proud to collaborate with the ELRIN consortium to explore the potential of Oxford Nanopore sequencing as a first-line diagnostic tool for #rarediseases and familial #cancers. The European Long Read Innovation Network (ELRIN) — a pioneering initiative led by the University of Tübingen and experts across Europe — aims to advance whole-genome Oxford #Nanopore sequencing (#WGS) for potential clinical diagnostics, addressing significant unmet healthcare needs. With 21 labs across 11 countries, ELRIN will help establish best practices, generate reference datasets, and assess the feasibility of Oxford Nanopore sequencing in routine clinical testing. Read more: https://lnkd.in/eARQC43r **Please note** Oxford Nanopore products are for research use only. Not for use in diagnostic purposes. #Genomics #RareDisease #PrecisionMedicine

Peter Coleman

Experienced Healthcare Marketer | Clinical background | Genomic Adoption and Education | Reproductive Health | Genetic Testing | Oncology |

2mo

An exciting time for clinical research and genomics, looking forward to increased diagnostic rates and improved outcomes for patients.

Matthew Ingenthron

QC Analyst, Advanced, Agilent Technologies

2mo

Please make your flow cells cheaper!

Robert Brooks

Connecting the biopharm industry ► Coordinating collaboration ► Accelerating change

2mo

Fantastic to see the application of this technology in this way - congrats to the Nanopore team

Like
Reply
See more comments

To view or add a comment, sign in

Explore content categories